Price$0.58+0.00 (+0.00%)
2026-03-092026-06-10
News · 26 weeks7-50%
2025-12-142026-06-07
Mix390d
- SEC Filings2(67%)
- Other1(33%)
Latest news
25 items- SECSEC Form 25-NSE filed by Synlogic Inc.25-NSE - SYNLOGIC, INC. (0001527599) (Subject)
- SECSEC Form 10-Q filed by Synlogic Inc.10-Q - SYNLOGIC, INC. (0001527599) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Synlogic Inc.10-K/A - SYNLOGIC, INC. (0001527599) (Filer)
- SECSEC Form 10-K filed by Synlogic Inc.10-K - SYNLOGIC, INC. (0001527599) (Filer)
- SECAmendment: Synlogic Inc. filed SEC Form 8-K: Other Events, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K/A - SYNLOGIC, INC. (0001527599) (Filer)
- SECSynlogic Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - SYNLOGIC, INC. (0001527599) (Filer)
- SECSynlogic Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - SYNLOGIC, INC. (0001527599) (Filer)
- SECSynlogic Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - SYNLOGIC, INC. (0001527599) (Filer)
- SECSEC Form 10-Q filed by Synlogic Inc.10-Q - SYNLOGIC, INC. (0001527599) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Synlogic Inc.SCHEDULE 13G/A - SYNLOGIC, INC. (0001527599) (Subject)
- SECSEC Form DEF 14A filed by Synlogic Inc.DEF 14A - SYNLOGIC, INC. (0001527599) (Filer)
- INSIDEROfficer Dooley Mary Beth sold $284 worth of shares (157 units at $1.81), decreasing direct ownership by 1% to 12,744 units (SEC Form 4)4 - SYNLOGIC, INC. (0001527599) (Issuer)
- SECSEC Form EFFECT filed by Synlogic Inc.EFFECT - SYNLOGIC, INC. (0001527599) (Filer)
- SECAmendment: SEC Form S-3/A filed by Synlogic Inc.S-3/A - SYNLOGIC, INC. (0001527599) (Filer)
- SECSEC Form S-3 filed by Synlogic Inc.S-3 - SYNLOGIC, INC. (0001527599) (Filer)
- SECSEC Form 10-Q filed by Synlogic Inc.10-Q - SYNLOGIC, INC. (0001527599) (Filer)
- SECSEC Form 10-Q filed by Synlogic Inc.10-Q - SYNLOGIC, INC. (0001527599) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Synlogic Inc.10-K/A - SYNLOGIC, INC. (0001527599) (Filer)
- INSIDERDirector Shea Richard P was granted 15,000 shares, increasing direct ownership by 2,964% to 15,506 units (SEC Form 4)4 - SYNLOGIC, INC. (0001527599) (Issuer)
- INSIDERDirector Flynn James P was granted 15,000 shares (SEC Form 4)4 - SYNLOGIC, INC. (0001527599) (Issuer)
- INSIDEROfficer Dooley Mary Beth sold $173 worth of shares (144 units at $1.20), decreasing direct ownership by 1% to 12,901 units (SEC Form 4)4 - SYNLOGIC, INC. (0001527599) (Issuer)
- SECSEC Form 10-K filed by Synlogic Inc.10-K - SYNLOGIC, INC. (0001527599) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Synlogic Inc.SCHEDULE 13G/A - SYNLOGIC, INC. (0001527599) (Subject)
- SECSynlogic Inc. filed SEC Form 8-K: Leadership Update8-K - SYNLOGIC, INC. (0001527599) (Filer)
- INSIDEROfficer Dooley Mary Beth sold $2,802 worth of shares (2,107 units at $1.33), decreasing direct ownership by 14% to 13,045 units (SEC Form 4)4 - SYNLOGIC, INC. (0001527599) (Issuer)
SYBX FAQ
7 questionsWhat does Synlogic Inc. do?
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that...Where does SYBX stock trade?
Synlogic Inc. (SYBX) is listed on NASDAQ.What sector and industry is SYBX in?
Synlogic Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Synlogic Inc. go public?
Synlogic Inc. (SYBX) completed its IPO in 2015.What are analysts saying about SYBX?
Synlogic Inc. has had 6 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $700.00 price target on 2021-11-24. Recent price targets range from $700.00 to $1100.00.What companies are similar to SYBX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SYBX side-by-side with any of them on Quantisnow.How can I track SYBX on Quantisnow?
Quantisnow aggregates Synlogic Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SYBX to receive live email and push alerts on every new disclosure.